Examination of the cost-effectiveness of rasagiline versus other approved first-line Parkinson disease therapies indicated that rasagiline was either cost saving or cost-effective in all cases.
Jane Castelli-Haley, PhD, MBA
Advertisement
Articles by Jane Castelli-Haley, PhD, MBA
Advertisement
Latest Updated Articles
- Cost-Effectiveness of Rasagiline Compared With First-Line Early Parkinson Disease Therapies
Published: June 9th 2012 | Updated:
Advertisement
Advertisement
